Illumina Signs Agreement to Acquire GenoLogics, Leader in Genomics Laboratory Information Management System Market
05 August 2015 - 6:05AM
Business Wire
Illumina, Inc. (NASDAQ:ILMN) today announced it has signed a
definitive agreement to acquire GenoLogics Life Sciences Software,
a developer of industry-leading laboratory information management
systems (LIMS) for life sciences organizations. The acquisition
strengthens Illumina’s industry leading portfolio of genetic
analysis solutions.
"The acquisition of GenoLogics demonstrates Illumina's
commitment to drive the adoption of sequencing in new markets and
improve the genomic information workflow," said Francis deSouza,
President of Illumina. "Adding GenoLogics’ products to Illumina’s
portfolio is another example of our continued commitment to bring
innovative sample-to-answer solutions to research and clinical
labs.”
Adopted by over 120 genomic labs worldwide, GenoLogics’ Clarity
LIMS™ software enables lab efficiencies and improved sample
throughput with increased accuracy, fast turnaround, sample
traceability, and preconfigured instrument integrations. GenoLogics
has a number of current partnerships with Illumina, including the
recently launched Clarity LIMS X, an edition of its
industry-leading laboratory informatics platform that is optimized
for use with Illumina SeqLab to address population-scale genomics
workflows.
“We are excited to join Illumina and carry on the innovative
spirit that GenoLogics Life Sciences Software has been known for,”
said Michael Ball, CEO of GenoLogics. “Illumina and GenoLogics have
had a longstanding partnership and this acquisition will enable us
to widen our distribution, accelerate our product development, and
provide even greater support to the Clarity LIMS community.”
GenoLogics will become part of the Illumina Enterprise
Informatics business under the leadership of Sanjay Chikarmane,
Senior Vice President and General Manager of Enterprise
Informatics.
The impact of this transaction was contemplated in the updated
2015 financial guidance Illumina provided on July 21, 2015. The
acquisition is expected to close by the end of August.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
Forward-Looking Statements
This release contains forward-looking statements that involve
risks and uncertainties, such as the expected closing date of the
acquisition. Important factors that could cause actual results to
differ materially from those in any forward-looking statements
include required closing conditions and the other factors detailed
in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time
of which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150804005242/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243rchambers@illumina.comorMedia:Eric Endicott,
858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2024 to May 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From May 2023 to May 2024